HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AN1284

anti-inflammatory compound that protects against D-galactosamine and lipopolysaccharide-induced liver injury in mouse model

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - AN1284: 4

Experts

1.	Weinstock, Marta: 3 articles (10/2021 - 10/2017)
2.	Weitman, Michal: 2 articles (10/2021 - 01/2020)
3.	Zeeli, Shani: 2 articles (10/2021 - 10/2017)
4.	Bejar, Corina: 1 article (10/2021)
5.	Melamed, Michal: 1 article (10/2021)
6.	Nudelman, Abraham: 1 article (10/2021)
7.	Weill, Tehilla: 1 article (10/2021)
8.	Yanovsky, Inessa: 1 article (10/2021)
9.	Gammal, Asaad: 1 article (01/2020)
10.	Hinden, Liad: 1 article (01/2020)

Related Diseases

1.	Acute Liver Failure (Fulminant Hepatic Failure) 10/01/2017 - "While both compounds are highly potent anti-inflammatory agents, AN1284 is more effective in mitigating the underlying causes of GalN/LPS-induced acute liver failure in mice."
2.	Inflammation (Inflammations) 01/01/2020 - "AN1284 improved kidney function in BSK-db/db animals by reducing albumin and creatinine and preventing renal inflammation and morphological changes. "
3.	Liver Diseases (Liver Disease) 10/01/2021 - "AN1284 can be given orally by a method of continuous release to treat chronic liver disease, and its preferential concentration in the liver should limit any adverse effects." 01/01/2023 - "This study determined whether an indoline derivative, AN1284, which significantly reduced damage in a model of acute liver disease, can reverse steatosis and fibrosis in mice with pre-existing NASH and explore its mechanism of action. "
4.	Fibrosis (Cirrhosis) 01/01/2023 - "In conclusion, chronic treatment with AN1284 (1mg/kg/day) reduced pre-existing steatosis and fibrosis through AhR, which affects several contributors to the development of fatty liver disease. " 01/01/2023 - "AN1284 (1 mg/kg/day) given by mps or in the drinking fluid significantly reduced fibrosis produced by carbon tetrachloride injections. " 01/01/2023 - "This study determined whether an indoline derivative, AN1284, which significantly reduced damage in a model of acute liver disease, can reverse steatosis and fibrosis in mice with pre-existing NASH and explore its mechanism of action. " 01/01/2023 - "AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line."
5.	Obesity 01/01/2020 - "Six-week-old BKS Cg-Dock 7m+/+ Leprdb/J mice with type 2 diabetes and obesity were treated with AN1284 (2.5 or 5 mg kg-1 per day) via micro-osmotic pumps implanted subcutaneously for 3 months. " 01/01/2020 - "In search of new remedies to reverse or arrest the progression of CKD, we examined the therapeutic potential of a novel compound, AN1284, in a mouse model of CKD induced by type 2 diabetes with obesity. "

Related Drugs and Biologics

1.	Creatinine
2.	Anti-Inflammatory Agents (Anti-Inflammatories)
3.	Albumins
4.	indoline
5.	Palmitic Acid (Hexadecanoic Acid)
6.	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)
7.	Lipids
8.	Carbon Tetrachloride (Tetrachloromethane)

Related Therapies and Procedures

1.	Injections